These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 16763468)

  • 41. Safety of gadoxetate disodium: Results from the clinical phase II-III development program and postmarketing surveillance.
    Endrikat JS; Dohanish S; Balzer T; Breuer JA
    J Magn Reson Imaging; 2015 Sep; 42(3):634-43. PubMed ID: 25643844
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers.
    Brismar TB; Dahlstrom N; Edsborg N; Persson A; Smedby O; Albiin N
    Acta Radiol; 2009 Sep; 50(7):709-15. PubMed ID: 19701821
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety of gadoterate meglumine (Gd-DOTA) as a contrast agent for magnetic resonance imaging: results of a post-marketing surveillance study in Japan.
    Ishiguchi T; Takahashi S
    Drugs R D; 2010; 10(3):133-45. PubMed ID: 20945944
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Baseline characteristics, diagnostic efficacy, and peri-examinational safety of IV gadoteric acid MRI in 148,489 patients.
    Braun J; Busse R; Darmon-Kern E; Heine O; Auer J; Meyl T; Maurer M; Hamm B; de Bucourt M
    Acta Radiol; 2020 Jul; 61(7):910-920. PubMed ID: 31739672
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Non-clinical assessment of safety and gadolinium deposition after cumulative administration of gadobenate dimeglumine (MultiHance
    Bussi S; Penard L; Bonafè R; Botteron C; Celeste R; Coppo A; Queliti R; Kirchin MA; Tedoldi F; Maisano F
    Regul Toxicol Pharmacol; 2018 Feb; 92():268-277. PubMed ID: 29278694
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety of gadoversetamide in patients with acute and chronic myocardial infarction.
    Huber S; Muthupillai R; Cheong B; Wible JH; Shah D; Woodard P; Grothues F; Mahrholdt H; Rochitte CE; Masoli O; Kim RJ; Schwaiger CM; Fuisz A; Kramer C; van Rossum AC; Biederman R; Lombardi M; Martin E; Kevorkian R; Flamm SD
    J Magn Reson Imaging; 2008 Dec; 28(6):1368-78. PubMed ID: 19025944
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Contrast-enhanced whole-heart coronary magnetic resonance angiography at 3.0 T: comparison with steady-state free precession technique at 1.5 T.
    Liu X; Bi X; Huang J; Jerecic R; Carr J; Li D
    Invest Radiol; 2008 Sep; 43(9):663-8. PubMed ID: 18708861
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interference of gadolinium-containing contrast-enhancing agents with colorimetric calcium laboratory testing.
    Löwe A; Balzer T; Hirt U
    Invest Radiol; 2005 Aug; 40(8):521-5. PubMed ID: 16024990
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA).
    Herborn CU; Honold E; Wolf M; Kemper J; Kinner S; Adam G; Barkhausen J
    Invest Radiol; 2007 Jan; 42(1):58-62. PubMed ID: 17213750
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevalence of acute adverse reactions to gadobutrol--a highly concentrated macrocyclic gadolinium chelate: review of 14,299 patients from observational trials.
    Forsting M; Palkowitsch P
    Eur J Radiol; 2010 Jun; 74(3):e186-92. PubMed ID: 19574008
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Postmarketing surveillance versus clinical trials: which benefits the patient?
    Lawson DH
    Cardiology; 1994; 85 Suppl 1():18-23. PubMed ID: 7743530
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children.
    Mosholder AD; Gelperin K; Hammad TA; Phelan K; Johann-Liang R
    Pediatrics; 2009 Feb; 123(2):611-6. PubMed ID: 19171629
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety assessment of gadoversetamide (OptiMARK) administered by power injector.
    Abdou N; Napoli AM; Hynes MR; Allen JC; Wible JH
    J Magn Reson Imaging; 2004 Jan; 19(1):133-40. PubMed ID: 14696230
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The hepatic safety and tolerability of the cyclooxygenase-2 selective NSAID celecoxib: pooled analysis of 41 randomized controlled trials.
    Soni P; Shell B; Cawkwell G; Li C; Ma H
    Curr Med Res Opin; 2009 Aug; 25(8):1841-51. PubMed ID: 19530981
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Magnetic resonance contrast agents for neuroimaging. Safety issues.
    Carr JJ
    Neuroimaging Clin N Am; 1994 Feb; 4(1):43-54. PubMed ID: 8130951
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
    Kisicki JC; Fiske K; Lyne A
    Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pediatric drug surveillance and the Food and Drug Administration's adverse event reporting system: an overview of reports, 2003-2007.
    Johann-Liang R; Wyeth J; Chen M; Cope JU
    Pharmacoepidemiol Drug Saf; 2009 Jan; 18(1):24-7. PubMed ID: 19009550
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gadobenate dimeglumine-enhanced MR angiography: Diagnostic performance of four doses for detection and grading of carotid, renal, and aorto-iliac stenoses compared to digital subtraction angiography.
    Schneider G; Ballarati C; Grazioli L; Manfredi R; Thurnher S; Kroencke TJ; Taupitz M; Merlino B; Bonomo L; Shen N; Pirovano G; Kirchin MA; Spinazzi A
    J Magn Reson Imaging; 2007 Oct; 26(4):1020-32. PubMed ID: 17896354
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A review of the safety profile of cefixime.
    Wu DH
    Clin Ther; 1993; 15(6):1108-19. PubMed ID: 8111808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.